Abstract
Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related deaths worldwide. Various molecular markers in NSCLC patients have been developed, including gene rearrangements, currently used in therapeutic strategies. With increasing number of these molecular biomarkers of NSCLC, there is a demand for highly efficient methods for detecting mutations and translocations in treatable targets. Those currently available U.S. Food and Drug Administration (FDA) approved approaches, for example imunohistochemisty (IHC) and fluorescence in situ hybridization (FISH), are inadequate, due to sufficient quantity of material and long time duration. Next-generation massive parallel sequencing (NGS), with the ability to perform and capture data from millions of sequencing reactions simultaneously could resolve the problem. Thanks to gradual NGS introduction into clinical laboratories, screening time should be considerably shorter, which is very important for patients with advanced NSCLC. Moreover, only a minimum sample input is needed for achieving adequate results. NGS was compared to the current detection methods of ALK, ROS1, c-RET and c-MET rearrangements in NSCLC and a significant match, between IHC, FISH and NGS results, was found. Recent available researches have been carried out on a small numbers of patients. Verifying these results on larger patients cohort is important. This review sumarizes the literature on this subject and compares current possibilities of predictive gene rearrangements detection in patients with NSCLC.
Highlights
Lung carcinoma is a heterogenous disease and a leading cause of death in both men and women worldwide[1]
Non-small cell lung carcinoma accounts for approximately 85-90% of all lung cancer
The importance of recognizing molecular subtypes is paramount for targeted therapy of anaplastic lymphoma kinase (ALK), reactive oxygen species 1 (ROS1), Tyrosineprotein kinase receptor Ret (c-RET) and Mesenchymal epithelial transition factor (c-MET) by specific tyrosine kinase inhibitors
Summary
Lung carcinoma is a heterogenous disease and a leading cause of death in both men and women worldwide[1]. It can be divided into two groups. Non-small cell lung carcinoma accounts for approximately 85-90% of all lung cancer. It is divided into adenocarcinomas (40-50%), squamous carcinomas (20-30%), large cell carcinomas and other uncommon carcinomas. At least 40% of these cases are diagnosed with advanced distant metastases. For this reason, it is crucial to implement new diagnostic methods[7,8,9]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.